secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2022-08-18T23:59:59+00:00
Accession:  0001683168-22-005897
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health reports positive Phase I MAD safety data for concussion drug PRV-002
--------------------------------------------------------------------------------

- PRV-002 was safe and well tolerated in 8 healthy volunteers given five daily doses.
- No severe adverse events; vital signs, EKG, and blood labs normal.
- Pharmacokinetics showed linear dose-concentration relationship and no drug accumulation.
- Safety Review Committee unanimously approved start of MAD Cohort II (higher dose).
- Low blood levels suggest intranasal delivery may target brain directly with fewer side effects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822005897/0001683168-22-005897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822005897/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-005897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer